Gastric Cancer Drugs Global Market Sees Growth Rate Of 16% Through 2022
20 May, 2022
The global gastric cancer drugs market size is expected to grow from $2.63 billion in 2021 to $3.05 billion in 2022 at a compound annual growth rate (CAGR) of 15.9%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global gastric cancer drug market size is expected to reach $5.18 billion in 2025 at a CAGR of 14.2%.
What is the Global Gastric Cancer Drugs Market?
The gastric cancer drugs market consists of sales of drugs for gastric cancer. Gastric cancer, also known as stomach cancer, is the formation of abnormal cells on the lining of stomach resulting in stomach pain and indigestion.
Get a Sample of the global gastric cancer drugs market report
What drives the Global Gastric Cancer Drugs Market?
Increasing number of obesity cases and smoking population increased number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to the estimates of American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.
Get the full global gastric cancer drugs industry report herehttps://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Global Gastric Cancer Drugs Market Segments
The global gastric cancer drugs market is segmented:
By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab
By End-User: Hospitals, Clinics, Others
By Route of Administration: Oral, Parenteral
By Geography: The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Gastric Cancer Drugs Global Market Report 2022 provides market size and growth forecasts for the global gastric cancer drugs market, global gastric cancer drugs market share, gastric cancer drugs market segments and geographies, gastric cancer drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The gastric cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Gastric Cancer Drugs Industry Players include Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche, GlaxoSmithKline PLC, Bristol-Myers Squibb, Sanofi, Pfizer Inc., AstraZeneca, Bayer Healthcare, Abbott, AROG Pharmaceuticals, Ipsen Biopharmaceuticals, Array Biopharma, Taiho Oncology, AstraZeneca, ARIAD Pharmaceuticals, Ono Pharmaceutical, Jiangsu HengRui Medicine, Gilead Bioscience, Celgene/Taiho, Boston Biomedical, Imugene Limited, Boehringer Ingelheim, Daiichi-Sankyo, Danaher corporation. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.